living literature
Research updates and alerts
Follow newly published governed evidence, regulatory records, and corrections. Draft, quarantined, and unresolved records do not appear here.
- Evidence added
Successful treatment with teduglutide for an adolescent with cerebral palsy accompanied by short bowel syndrome.
Teduglutide · insufficient · DOI 10.1111/ped.15894 · PMID 40019443
- Evidence added
Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina.
Teduglutide · insufficient · DOI 10.4292/wjgpt.v16.i4.110642 · PMID 41378076
- Evidence added
Comment on "real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure".
Teduglutide · insufficient · DOI 10.1016/j.clnesp.2026.105083 · PMID 42674361
- Evidence added
PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.
Teduglutide · insufficient · DOI 10.1002/jpr3.70144 · PMID 42110144
- Evidence added
Teduglutide in Enterocolitis Secondary to Graft-Versus-Host Disease Post-Bone Transplant: Case Report
Teduglutide · insufficient · DOI 10.20944/preprints202602.1566.v1
- Evidence added
Effectiveness and Safety of Teduglutide Treatment in Adult Patients with Short Bowel Syndrome: A Case Series and Review of Current Evidence.
Teduglutide · insufficient · DOI 10.3390/jcm15052033 · PMID 41827448
- Evidence added
Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study.
Teduglutide · insufficient · DOI 10.1038/s41390-026-05489-0 · PMID 42754721
- Evidence added
Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome.
Teduglutide · insufficient · DOI 10.4292/wjgpt.v17.i1.117071 · PMID 41809219
- Evidence added
Add-on to current guidelines for monitoring of SBS patients treated with teduglutide
Teduglutide · insufficient · DOI 10.1038/s44355-025-00047-7
- Evidence added
Dextran Sulfate/Pramlintide Polyelectrolyte Nanoparticles as a Promising Delivery System: Optimization, Evaluation of Supramolecular Interactions and Effect on Conformational Stability of the Peptide Drug
Pramlintide · insufficient · DOI 10.21577/0103-5053.20210062
- Evidence added
Ultra-fast insulin-pramlintide co-formulation for improved glucose management in diabetic rats
Pramlintide · insufficient · DOI 10.1101/2021.04.12.439573
- Evidence added
Slow post-induction specific growth rate enhances recombinant protein expression in Escherichia coli: Pramlintide multimer and ranibizumab production as case studies
Pramlintide · insufficient · DOI 10.1016/j.procbio.2022.01.009
- Evidence added
Effect of Zn(II) on pramlintide: structural kink, fibril formation, antifungal activity
Pramlintide · insufficient · DOI 10.21203/rs.3.rs-1954176/v1
- Evidence added
Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles.
Pramlintide · insufficient · DOI 10.4103/1735-5362.359428 · PMID 36704426
- Evidence added
Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Systematic Review
Pramlintide · insufficient · DOI 10.3390/app122010262
- Evidence added
Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide.
Pramlintide · insufficient · DOI 10.3390/pharmaceutics14030553 · PMID 35335929
- Evidence added
Linaclotide for Bowel Preparation: Is "Afterload Reduction" Not Just for Heart Failure Anymore?
Linaclotide · insufficient · DOI 10.14309/ajg.0000000000003375 · PMID 40110861
- Evidence added
Polysaccharide-peptide complexes stabilized around nanoemulsion droplets: A new approach for nasal delivering of pramlintide and insulin
Pramlintide · insufficient · DOI 10.1016/j.jddst.2023.104527
- Evidence added
QBD Approach for Design and Characterization of Pramlintide Microspheres for Controlled Drug Release
Pramlintide · insufficient · DOI 10.1007/s12247-023-09795-6
- Evidence added
Partially differentiated enterocytes in ileal and distal-colonic human F508del-CF-enteroids secrete fluid in response to forskolin and linaclotide
Linaclotide · insufficient · DOI 10.1101/2025.02.03.636268
- Evidence added
Beyond the injection: delivery systems reshaping retinal disease management.
Elamipretide · insufficient · DOI 10.1080/14656566.2025.2496424 · PMID 40319468
- Evidence added
Oral delivery of the amylin receptor agonist pramlintide
Pramlintide · insufficient · DOI 10.1101/2023.11.09.566408
- Evidence added
A pharmacovigilance study of the association between linaclotide/plecanatide and muscle spasms based on food and drug administration adverse event reporting system.
Linaclotide · insufficient · DOI 10.3389/fphar.2025.1635792 · PMID 40843382
- Evidence added
Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease.
Pramlintide · insufficient · DOI 10.1016/j.ijbiomac.2024.136158 · PMID 39362444
- Evidence added
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database.
Linaclotide · insufficient · DOI 10.1080/14740338.2025.2519833 · PMID 40503810
- Evidence added
Correction to: Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK‑3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high‑fat dietstreptozocin rat model.
Pramlintide · insufficient · DOI 10.1007/s00424-024-02959-4 · PMID 38575720
- Evidence added
Clinical Study on the Application of Low-Dose 2L Lactulose Combined with Linaclotide in Bowel Preparation Before Colonoscopy
Linaclotide · insufficient · DOI 10.21203/rs.3.rs-7391900/v1
- Evidence added
Efficacy of linaclotide as adjunct for bowel preparation in patients with chronic constipation: a pre-specified analysis of the APPLE trial.
Linaclotide · insufficient · DOI 10.5946/ce.2026.214 · PMID 42681900
- Evidence added
Efficacy and safety of Guanylyl cyclase C agonists (linaclotide and plecanatide) in patients with irritable bowel syndrome with constipation: a systematic review and meta-analysis of randomized controlled trials.
Linaclotide · insufficient · DOI 10.3389/fphar.2026.1761301 · PMID 42038325
- Evidence added
Efficacy and safety of linaclotide plus polyethylene glycol for bowel preparation before colonoscopy in elderly Chinese patients: a systematic review and meta-analysis.
Linaclotide · insufficient · DOI 10.3389/fmed.2026.1833539 · PMID 42482900
- Regulatory record
Thymosin beta-4 — European Union — EMA
European Medicines Agency medicines database
- Regulatory record
Thymosin beta-4 — United States — FDA
FDA Drugs@FDA database
- Regulatory record
Pramlintide — European Union — EMA
European Medicines Agency medicines database
- Regulatory record
Pramlintide — United States — FDA
FDA SYMLIN (pramlintide acetate) prescribing information
- Regulatory record
Pemvidutide — United States — FDA
FDA Drugs@FDA database
- Regulatory record
Pemvidutide — European Union — EMA
European Medicines Agency medicines database
- Regulatory record
Mazdutide — China — NMPA
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
- Regulatory record
Mazdutide — United States — FDA
FDA Drugs@FDA database
- Regulatory record
Glucagon — United States — FDA
FDA GlucaGen (glucagon) prescribing information
- Regulatory record
Glucagon — European Union — EMA
European Medicines Agency: Baqsimi (glucagon)